Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.
Commentary|Articles|January 23, 2026
AJMC® in the Press, January 23, 2026
Author(s)Julia Bonavitacola
Listen
0:00 / 0:00
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An article from
Advertisement
Related to this article
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.
A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when disease relapsed as AML after transplant.
Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients with MASH in 3 US data sets.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
3
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
4
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
5